Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Trial Profile

Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 31 May 2017 Results (n= 452) assessing optimal lenvatinib dose based on population PK and exposure-response analysis using using pooled data from NCT00946153, NCT00121719, NCT00121680, NCT00280397, NCT01268293 and other 8 phase 1 studies in healthy adults, published in the Journal of Clinical Pharmacology
    • 21 Jan 2017 Results of subgroup analysis of the phase 2 part of this study (NCT00946153) presented at the 2017 Gastrointestinal Cancers Symposium
    • 27 Oct 2015 Phase I primary endpoint has been met, n=20. (Maximum tolerated dose and recommended phase II dose.)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top